Calypso Biotech (Exit)

Calypso specialized in therapies for severe autoimmune diseases. Its lead program, CALY-002, is a best-in-class IL-15 antibody in development for eosinophilic esophagitis (EoE) and other immune-mediated disorders. Calypso was acquired by Novartis in 2024.